Harrow Acquires TYRVAYA® Global Rights for Up to $100M

Harrow, Inc. has entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray, an FDA-approved treatment for dry eye disease. The acquisition involves an upfront cash payment of $30 million, with potential contingent milestone payments of up to an additional $70 million based on net sales, totaling up to $100 million. This strategic move expands Harrow's dry eye portfolio, complementing its VEVYE franchise by offering a differentiated treatment option and leveraging existing commercial infrastructure. The upfront payment will be funded with cash on hand, and the transaction is expected to close in the second half of 2026.